Creative Planning Invests $54,000 in OraSure Technologies, Inc. (NASDAQ:OSUR)

Creative Planning purchased a new position in OraSure Technologies, Inc. (NASDAQ:OSUR) in the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 12,728 shares of the medical instruments supplier’s stock, valued at approximately $54,000.

A number of other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of OraSure Technologies by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 5,409,028 shares of the medical instruments supplier’s stock worth $33,266,000 after purchasing an additional 99,572 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of OraSure Technologies by 20.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,288,443 shares of the medical instruments supplier’s stock worth $9,749,000 after purchasing an additional 391,100 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of OraSure Technologies by 38.1% in the 2nd quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier’s stock worth $9,349,000 after purchasing an additional 605,324 shares in the last quarter. Millennium Management LLC raised its holdings in shares of OraSure Technologies by 727.5% in the 2nd quarter. Millennium Management LLC now owns 2,021,126 shares of the medical instruments supplier’s stock worth $8,610,000 after purchasing an additional 1,776,867 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of OraSure Technologies by 30.1% in the 2nd quarter. American Century Companies Inc. now owns 1,809,897 shares of the medical instruments supplier’s stock worth $7,710,000 after purchasing an additional 418,603 shares in the last quarter. 93.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Evercore ISI boosted their target price on shares of OraSure Technologies from $4.50 to $5.00 and gave the stock an “in-line” rating in a report on Wednesday, August 7th. StockNews.com upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a report on Friday, October 4th.

OraSure Technologies Price Performance

OSUR stock opened at $4.05 on Thursday. OraSure Technologies, Inc. has a 52-week low of $3.91 and a 52-week high of $8.45. The company’s 50 day simple moving average is $4.20 and its 200-day simple moving average is $4.43. The firm has a market capitalization of $302.09 million, a P/E ratio of 27.00 and a beta of 0.05.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The business had revenue of $39.92 million for the quarter, compared to analyst estimates of $38.97 million. During the same quarter in the previous year, the business earned $0.27 earnings per share. The firm’s revenue was down 55.2% compared to the same quarter last year. Sell-side analysts predict that OraSure Technologies, Inc. will post -0.11 EPS for the current fiscal year.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.